Back from ASH 2025, Dr Suchitra Sundaram reports on notable frontline CLL data. Time‑limited pirtobrutinib combined with venetoclax and obinutuzumab produced high rates of undetectable minimal ...

A short film that premiered earlier this month tracks the journeys of three people who discovered a renewed commitment to living their lives to the fullest after being diagnosed with chronic ...

Schlossberg says she was diagnosed shortly after welcoming her second child. Tatiana Schlossberg's surprising revelation that she is battling terminal cancer has put a spotlight on the type of cancer ...

Bottom Line: Adding the investigational antibody ianalumab (VAY736) to ibrutinib (Imbruvica) allowed some patients with chronic lymphocytic leukemia (CLL) to discontinue daily therapy and potentially ...

As a diehard enthusiast of video games, Ediz Guner has been attentively following the ebbs and flows of the gaming industry for a long period of time. This, coupled with his hobby of extensively ...

Danganronpa 2: Goodbye Despair is making a comeback in the form of Danganronpa 2x2 for PC via Steam, Nintendo Switch, Switch 2, PlayStation 5, and Xbox Series X and S. Spike Chunsoft announced a ...

Pirtobrutinib was associated with a statistically significant improvement in PFS compared with bendamustine plus rituximab therapy. Topline data were announced from a phase 3 trial evaluating ...

Jaypirca demonstrated superior overall response rates and progression-free survival trends compared to Imbruvica in the BRUIN CLL-314 trial for CLL/SLL patients. The trial is the first head-to-head ...

Senior Lecturer of Exercise Immunology, Faculty of Health and Medical Sciences, School of Biosciences, University of Surrey CLL starts when a type of immune cell called a B cell – normally responsible ...

Prompt recognition of autoimmune disease symptoms can help patients with chronic lymphocytic leukemia receive proper rheumatologic care. Immune dysregulation associated with chronic lymphocytic ...

Combination therapies for chronic lymphocytic leukemia (CLL) offer improved depth of response and potentially longer survival times compared with single-agent treatments. They target different ...